Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned a consensus rating of “Moderate Buy” from the seventeen analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eleven have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $35.1429.

Several equities analysts have commented on DYN shares. JPMorgan Chase & Co. cut their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Evercore lowered their target price on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, December 15th. Morgan Stanley cut their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Oppenheimer raised shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $11.00 to $40.00 in a research note on Wednesday, December 10th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Brian S. Posner purchased 3,000 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was purchased at an average price of $15.06 per share, with a total value of $45,180.00. Following the completion of the purchase, the director owned 11,500 shares of the company’s stock, valued at approximately $173,190. The trade was a 35.29% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DYN. Chung Wu Investment Group LLC purchased a new stake in shares of Dyne Therapeutics in the 3rd quarter worth $30,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after buying an additional 1,109 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $84,000. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after acquiring an additional 955 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Up 6.1%

Shares of NASDAQ DYN opened at $18.13 on Wednesday. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $25.00. The firm has a 50-day simple moving average of $17.11 and a two-hundred day simple moving average of $17.70. The company has a market cap of $2.99 billion, a P/E ratio of -5.12 and a beta of 1.34. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.